The Conversation (0)
Scilex Announces Pricing and Availability of ZTlido for the Commercial Launch of its First Product in October of 2018
Sep. 19, 2018 09:00AM PST
Pharmaceutical Investing
Scilex Pharmaceuticals a subsidiary of Sorrento Therapeutics (NASDAQ: SRNE) announced that the Wholesale Acquisition Cost (WAC) for ZTlido (lidocaine topical system) 1.8% (ZTLIDO) is $8.98 per patch and is now listed in pricing compendia. Scilex expects commercial availability of ZTlido through wholesale distribution in October 2018. As quoted in the press release: “We are excited …
Scilex Pharmaceuticals a subsidiary of Sorrento Therapeutics (NASDAQ: SRNE) announced that the Wholesale Acquisition Cost (WAC) for ZTlido (lidocaine topical system) 1.8% (ZTLIDO) is $8.98 per patch and is now listed in pricing compendia. Scilex expects commercial availability of ZTlido through wholesale distribution in October 2018.
As quoted in the press release:
“We are excited to bring our first commercial product to the market,” said George Ng, President, Business, of Scilex. “With ZTlido, we are proud to offer a non-opioid alternative and option for patients with post-herpetic neuralgia.”
ZTLIDO is a topical product that uses an advanced adhesion technology providing more efficient lidocaine delivery than Lidoderm® over a full 12 hours. Post-herpetic neuralgia (PHN), also referred to as post-shingles pain, is a frequent complication of shingles, a condition caused by the herpes zoster (HZ) virus, which afflicts an estimated 1 million people each year in the US.
